AML

Criteria to qualify for study: Drug used in study:
  • Relapsed of refractory AML; previously untreated AML not suitable for intensive Induction.

HR 41

A Phase 1/2, Open label, Mulitcenter 2 part study to access the safety, tolerability, Pharmaconetics, and efficacy, of AZD2811 Nanoparticle as Monotherapy or in combination in treatment – naïve or relapsed/refractory Acute Myeloid Leukemia.

Criteria to qualify for study: Drug used in study:
  • Newly diagnosed AML not previously treated or AML in remission after induction.

AML 47

A phase lb/ll Study evaluating the safety and efficacy of idasanutlin in combination with Cytarabine and Daunorubicin in patients newly diagnosed with Acute Myeloid leukemia (AML) and the safety and efficacy of Idasanutlin in the maintenance of first AML complete remission.

Criteria to qualify for study: Drug used in study:
  • R/R, AML/MM/DLBCL

Hemeref51 Medimmune

A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MEDI7247 in Patients with Selected Relapsed/Refractory Hematological Malignancy "ECOG 0-1, Liver Function Tests: AST and ALT ? 3 × ULN; ? 5 × the ULN for either value if due to leukemia or lymphoma involvement, and serum TBL ? 1.5 × ULN, unless consistent with Gilbert’s syndrome (ratio between total and direct bilirubin > 5), for which TBL ? 2.5 × ULN is allowed. AML - Hydroxyurea, if clinically indicated, is permitted but must be stopped 24 hours prior to the first scheduled dose of MEDI7247 MM-May have received approved agents or radiation within 14 days OR immunotherapy within 28 days of the first scheduled dose of MEDI7247"

Criteria to qualify for study: Drug used in study:
  • First line treatment
  • Low blast count

MDS 21

Phase 3, Randomized, Controlled, Open label, Clinical Study of Pevonedistat Plus Azacitidine versus single agent Azacitidine as First-Line treatment for patients with higher risk Myelodysplatic Syndrome, Chronic Myelomonocytic Leukemia, of Low Blast Acute Myelogenous Leukemia.